In January 2017, Sarah Cannon, the Cancer Institute of Hospital Corporation of America (HCA) announced that Genospace, LLC, a cloud-based software company focused on advancing personalized medicine, would merge with its organization and become a wholly-owned subsidiary. By joining forces, the effort will be to have Sarah Cannon and Genospace together harness and use molecular profiling data to more effectively match cancer patients to cutting-edge therapies in clinical trials. Describing themselves as Digital Architects of Genomic Medicineâ¢. GenoSpace has been a precision medicine software company developing a comprehensive suite of offerings for securely storing genomic and health data, and providing it in formats specific to its diverse user communities. GenoSpace for Clinical⢠and GenoSpace for Labs⢠facilitate clinically actionable interpretation and report generation for precision medicine. GenoSpace for Research⢠provides dynamic analysis, visualization and collaboration tools on an advanced population analytics platform. GenoSpace for Patient Communities⢠enables patient-centric exploration and advancement of personalized m
